Ascendiant analyst Edward Woo initiated coverage of Synergy CHC (SNYR) with a Buy rating and $5 price target Synergy provides consumer health care, beauty, and lifestyle products, the analyst tells investors in a research note. The firm sees large market opportunities for the company’s brain health supplement FOCUSfactor.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNYR: